Sarepta Therapeutics (SRPT) Tops Q4 EPS by 36c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($0.77), $0.36 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $201.5 million versus the consensus estimate of $198.61 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• UBS Upgrades Bajaj Finance Ltd. (BAF:IN) to Neutral
• Franklin BSP Realty Trust (FBRT) Reiterated at Market Outperform by Citizens